Janux Q2 2026: $970.9M Cash, Pipeline Progress, JANX013 on Track for H2 Initiation
JANX sits 31% above its 52-week low of $12.12.
Summary
Janux Therapeutics reported Q2 2026 financial results with $970.9 million in cash and a narrowed net loss. The company provided pipeline updates, including continued enrollment across its prostate cancer programs and upcoming milestones for JANX011 and JANX013.
Key Events · Earnings and Guidance · JANX
-
Q2 2026 Financial Results
Net loss narrowed to $22.0M from $33.9M in Q2 2025. Cash and short-term investments totaled $970.9M as of June 30, 2026, down slightly from $966.6M at year-end 2025.
-
Pipeline Progress
JANX007 Phase 1b enrollment continues in taxane-naïve mCRPC monotherapy and darolutamide combination cohorts. JANX014 Phase 1 study enrolling mCRPC patients. JANX011 Phase 1 healthy volunteer study progressing.
-
Upcoming Milestones
Initial clinical data for JANX011 expected in H2 2026. JANX013 clinical initiation expected in H2 2026. Additional JANX007 data expected at a medical congress in H1 2027.
-
Strong Cash Position
$970.9M in cash and short-term investments provides runway to advance multiple clinical programs without near-term financing risk.
Analysis · JANX · Life Sciences
Janux reported Q2 2026 results with a net loss of $22.0 million, narrowing from $33.9 million a year ago. The company holds $970.9 million in cash, providing a multi-year runway to advance its oncology and autoimmune pipeline. Key clinical updates include continued enrollment in JANX007 and JANX014 prostate cancer trials, progress in the JANX011 healthy volunteer study, and confirmation that JANX013 remains on track for clinical initiation in the second half of 2026. The strong balance sheet and upcoming data catalysts position the company for potential value inflection, though execution risk remains typical for clinical-stage biotech.
At the time of this filing, JANX was trading at $15.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $981.8M. The 52-week trading range was $12.12 to $35.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.